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Abstract
Background: During the last decade, oral bisphosphonates (BP) became the most widely prescribed
pharmacologic class for post-menopausal osteoporosis. However, many surveys revealed the important issue of
poor persistence with those drugs resulting in a failure of treatment to reduce fracture risk sufficiently. Using a
published Markov model, this study analyses the economic impact of non-persistence with bisphosphonates in the
context of the introduction of generics in France.
Methods: Direct costs of vertebral, hip and wrist fracture were assessed and included in an existing 10-year Markov
model developed to analyse consequences of non-persistence. Three alternatives of comparison were set: no
treatment, real-world persistence, and ideal persistence. Simulated patients’ characteristics matched those from a French
observational study and the real-world adherence alternative employed persistence data from published database
analysis. The risk of fracture of menopausal women and the risk reduction associated with the drugs were based on
results reported in clinical trials. Incremental cost-effectiveness ratios (ICERs) were calculated first between real-world
adherence and no treatment alternatives, and second between ideal and real-world persistence alternatives. The cost of
non-persistence was defined as the difference between total cost of ideal and real-world persistence alternatives.
Results: Within fractured women population, mean costs of 10-year management of fracture were significantly
different between the three alternatives with €7,239 (± €4,783), €6,711 (± €4,410) and €6,134 (± €3,945) in the no-
treatment, the real-world and ideal persistence alternatives, respectively (p < 0.0001). Cost-effectiveness ratio for
real-world treatment persistence compared with no-treatment alternative was found dominant and as well,
alternative of ideal persistence dominated the former. Each ten percentage point of persistence gain amounted to
€58 per patient, and extrapolation resulted in a global annual cost of non-persistence of over €30 million to the
French health care system, with a substantial transfer from hospital to pharmacy budgets.
Conclusion: Within term, improving persistence with oral bisphosphonates should be economically dominant on
levels currently known in real-world. Given this potential savings, ambitious adherence-enhancing interventions
should be considered in osteoporotic patients.
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Background
Osteoporosis is characterised by low bone mass and
microarchitectural deterioration of bone responsible for
8.9 million fractures each year worldwide [1]. With at
least 150,000 clinical fractures every year, preventing
osteoporosis within elderly represents an important
issue for public health stakeholders in France [2]. This
was brought to light in 2007 by reimbursement deci-
sions for osteoporosis screening (i.e. bone mineral densi-
tometry examination) and for primary prevention (i.e.
osteoporotic patient without fracture history).
Randomized clinical trials providing evidence for clinical
relevant fracture protection by the bisphosphonates [3,4],
international guidelines recommended bisphosphonates
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late 1990s [5]. During the following decade, bisphospho-
nates became the most widely prescribed pharmacologic
class for this pathology [6], with nearly 80% of specific
drug prescriptions [7] and also corresponding to over
€300 million reimbursement by French health system
(called Assurance Maladie) for 2008 [8]. Recently, authori-
ties stress the pressure on oral bisphosphonates prices
strengthened by near future genericisation of the whole
class, as it already occurred in 2008 to the first historical
molecule (i.e. alendronate).
Post-menopausal osteoporosis prevalence was esti-
mated at around 30% in women fifty years of age and
over [9]. In 2006, a study in French general population
showed that this diagnosis was already done to almost
10% of those women highlighting an underdiagnosis
issue [10]. At the time of this survey, only 61% claimed
receiving an osteoporosis treatment also revealing a sig-
nificant health management issue with those drugs, in
accordance to many other findings [11]. A report of data
pooled from the US, UK and France also revealed a one-
year discontinuation rate of approximately 50% in
women treated with bisphosphonates [12]. Alarmed by
low rates of treatment adherence in developed countries
for many chronic diseases such as osteoporosis, the
World Health Organisation has emphasised the growing
body of evidence that supports the notion that increasing
the effectiveness of adherence interventions may have a
far greater impact on the health of the population than
any improvement in the efficacy of specific medical treat-
ments [13]. An expert consensus in osteoporosis defined
adherence as a general term encompassing both compli-
ance and persistence [14]. The International Society for
Pharmacoeconomic and Outcomes Research (ISPOR)
tended to consider terms “adherence” and “compliance”
a ss y n o n y m[ 1 5 ]r e p r e s e n t i n g“the extent to which a
patient acts in accordance with the prescribed interval
and dose of a dosing regimen”. Persistence was defined
as “the duration of time from initiation to discontinua-
tion of therapy” which corresponds to a continuous vari-
able (i.e. number of days with drug availability) or a
dichotomous variable (i.e. being “persistent” or “nonper-
sistent” at the end of a predefined time period). Graphical
illustration of persistence is generally performed accord-
ing survival analysis following the Kaplan-Meier method
so called persistence curve [14].
Although non-persistence was found to systematically
reduce treatment effectiveness, this issue was not often
taken into account in pharmacoeconomic models [16].
On behalf of the Economics of Medication Compliance
Working Group of ISPOR, Hughes et al. [17] have formu-
lated methods that may be appropriate for integrating
these aspects in economic evaluations. Especially, Markov
models were identified to allow direct inclusion of
persistence variable in the analysis, as patients transit
during each cycle. In 2009, such model was designed to
simulate the impact of improving persistence rates on
osteoporosis treatment effectiveness [18]. Compared to a
non-treatment hypothesis, the relative risk of fracture
over ten years was 0.83 for weekly bisphosphonate treat-
ment and decreased to 0.73 if hypothetical full-treatment
persistence was achieved. Moreover, improving persis-
tence by 20% was found to have the same clinical impact
as a 20% increase in clinical efficacy. In observational stu-
dies, women considered as persistent appeared to benefit
from a significant decrease of fracture risk ranging from
26% to 32% when compared to nonpersistent ones
[19-21]. Nonpersistent patients (i.e. under one-year com-
pliance) were shown to be associated with higher hospita-
lization rates and higher charges for in-and outpatient
health care resources [22]. However, drug expenditures
related to non-persistence rates appeared lower [21] and
impact of overall incremental direct costs and savings on
healthcare budget remains unclear. To our knowledge,
no previous study proposed a global approach to estimate
cost of non-persistence in the field of osteoporosis.
The modelling study described here proposes an estima-
tion of the budget impact of non-persistence with bispho-
sphonates, by assessing cost-effectiveness of “ideal
persistence” compared to current persistence in real-world
and estimating the annual total cost of non-persistence for
France.
Methods
Model Structure
This modelling study used a validated Markov model
that has been developed (TreeAge Software, Williams-
town, MA, USA) to predict the incidence of osteoporo-
tic fractures in women with post-menopausal
osteoporosis (PMO) in relation with persistence rates
with bisphosphonates [18]. The main adaptation is that
cost information was linked to the model by assigning
each Markov state rewards for costs. These rewards
contributed to the total accumulated sum of costs
depending on the patient’s path through the health
states.
Costs and events were firstly estimated for three alter-
natives: no-treatment, real-world persistence, and ideal
persistence. No-treatment alternative modelized the nat-
ural history of PMO without assistance of any pharma-
cologic therapy. The ideal persistence alternative
considered bisphosphonates benefits from clinical trials.
The real-world persistence alternative assumed all
patients were treated by weekly or monthly bisphospho-
nates and was based on current persistence rates from
observational studies. Costs of fractures management
and rehabilitation were also added as well as costs of
bisphosphonates as per the persistence rate.
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hip, the vertebrae and the wrist, since these are the
specific sites where the most frequent osteoporotic
fractures occur [23] and were particularly well docu-
mented compared to less common sites. Morphometric
(ie identified by radiography) and symptomatic (ie
clinically diagnosed) vertebral fractures were differen-
tiated. Input variables for the model included the pre-
valence of diagnosed PMO, fracture rates at the sites
of interest, efficacy and residual beneficial effect of
bisphosphonate treatment, and treatment persistence
rates. Fracture events were modelled over a ten-year
period.
Key model characteristics were as follows. Markov state
transitions consisted in four mutually exclusive health
states with a probability of experiencing different fracture
events i.e. diagnosed PMO, post-hip fracture, post-ver-
tebral fracture and post-wrist fracture (Figure 1). For
every patient and at any 1-year cycle, death could end the
simulation. This was developed to simulate the number
of osteoporotic hip, vertebral, and wrist fractures as a
function of demographic change and other influences.
This model was analysed using individual, first-order
Monte Carlo simulation, and was pre-designed to be
adaptable for assessing the impact of non-persistence
improvement on cost.
Transition probabilities
Transition probabilities between the different health
states were defined in the model by features of the
French patients diagnosed with PMO in terms of age dis-
tribution and proportion of patients with a prior fracture
[7]. Annual absolute fracture risks in women with post-
menopausal osteoporosis were from estimations based
on general population data [24] and relative risk ratios
for the association between subsequent and prior frac-
tures from a meta-analysis [25]. Pooled bisphosphonates
efficacies for each fracture sites were given by the Health
Technology Assessment guidance for health economic
models in osteoporosis [26]. Residual effect data from a
follow-up of postmenopausal Danish women during 7
years after treatment withdrawal [27] were modelized to
determine the relation of treatment duration and treat-
ment global protection i.e. 10-year protection achieved
with around 4 years of continued treatment [18].
Insertion of persistence with bisphosphonates treat-
ments occurred in this model only for real-world alterna-
tives. Data were from the Longitudinal Patient Database
(LPD) which is constituted by a French representative
network of over 1,200 computerized general practitioners
(Thales network). Analyses of treatment discontinuation
within women newly treated with weekly bisphospho-
nates showed that 49% of them were nonpersistent after
Figure 1 Markov model structure.
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Page 3 of 101-year of follow-up [12] and this rate increased to 59%
after 2 years [28]. Persistence curves were extrapolated
using the best-fit logarithmic derivations from which
functions were combined with those of residual protec-
tion following interruption of treatment. Proportion of
women with effective protection at each cycle of simula-
tion was then calculated to allow the path of patients
from the initial model (Figure 1 - Part A) where they
benefit from treatment protection to a twin model
(Figure 1 - Part B) where it is not the case anymore.
Alternatives as ideal persistence and no-treatment have
been individually run in one of the two parts giving
extreme values this proportion, respectively one and null.
Baseline age-specific, all-cause mortality rates were
derived from 2004 (French national population statistics,
INSEE). Mortality following a hip fracture was estimated
by adjusting baseline, age-specific, and all-cause mortal-
ity using Swedish data [26]. Concerning vertebral frac-
tures, relative risks of mortality in the subsequent year
was taken from the European Prospective Osteoporosis
Study (EPOS) [29]. This model did not apply incremen-
tal mortality to the post-wrist fracture state as neither
early nor medium term mortality has been shown [30].
Primary data inputs are summarized in Table 1
including references.
Costs
All costs are given in Euro (€) for the year 2010. An
annual discount rate of 5% was used. A sensitivity analy-
sis was also performed without any discounting.
Cost of bisphosphonate treatments were set based on
the public price in 2010 extracted from the Caisse
Nationale d’Assurance Maladie database [31]. The
French authorities have approved generic forms of alen-
dronate 70 mg in 2006 [32], and although risedronate is
still protected by a market patent, the base case model
assumed by default the generic price of alendronate for
bisphosphonates corresponding to €52.23 for 12 weeks
of treatment. In a sensitivity analysis, risedronate
branded price of €87.46 for 12 weeks was also tested. In
the ideal persistence alternative, drug costs were equal
to one year of medication at each cycle, whereas in the
real-world persistence alternative, those costs were mul-
tiplied by persistence rates associated for each cycle.
Considering all vertebral fractures, only 23% were con-
sidered to be symptomatic [44] and were assumed to
use medical resources. No cost/reward was given to
other morphometric-defined vertebral fractures. Because
of the lack of accurate data in the literature, cost of
symptomatic fractures management in France was esti-
mated. Calculations were based on the medicalization
program information system (PMSI) [33] and the
National Cost Study (Etude Nationale de Coûts) [34]
which are the two independent general sources of infor-
mation currently available in France about public and
private hospital activity and costs. Disease-related
groups (DRG) attributed to patients with vertebral frac-
tures as main diagnosis for hospitalizations in 2008 were
collected from the PMSI database. National Cost Study
which integrates the results of detailed accounting data
on a national sample of French hospitals gave cost per
each DRG. Those data allowed the calculation of frac-
ture hospitalization cost by weighted average. Although
more data are available about non-vertebral fractures,
costs of hip and wrist fractures were assessed by the
same way for consistency and to validate this method.
In PMSI database, two principal ICD 10 diagnostics of
hospitalization were used to code both hip fractures (e.
g. S720 and S7200) and wrist fracture (e.g. S525 and
S526). Vertebral fractures were classified among 21 prin-
cipal diagnosis (e.g. main prefix: M485, S220, S221,
S320, S327 and, S328). Incidences of fractures encoded
by principal diagnosis in the PMSI 2007database were as
follow: 26,490 at vertebra, 53,376 at hip and 10,394 at
wrist. More than 95% of those cases were associated
with respectively 12, 8 and 10 different DRGs. For each
fracture site, average costs of hospitalisation and global
management including rehabilitation [35] were esti-
mated and presented in Table 2.
A Student t-test was performed to compare mean
values of cost with a significance threshold P value of
0.05.
Analyses
Ten-year period was considered as an appropriate hori-
z o ni nt h ef i e l do fo s t e o p o r o s i s[ 3 6 ] ,a n dt h em o d e l
simulations were also ran over 10 cycles. After stability
of the model was checked using predictable random
sequences, 30,000 Monte Carlo microsimulations were
performed for each alternative, and fractures, costs, and
deaths were recorded.
As a primary analysis, incremental cost-effectiveness
ratios (ICERs) were calculated first between real-world
adherence and no treatment alternatives, and second
between ideal and real-world persistence alternatives as
described in the following formulas:
ICERReal - world persistence =
µCReal - world persistence − µCNo treatment
µEReal - world persistence − µENo treatment
ICER Ideal persistence =
µCIdeal persistence − µCReal - world persistence
µEIdeal persistence − µEReal - world persistence
Cost criterion (μC) encompassed both management of
fracture as well as drug consumption, while two effec-
tiveness criteria (μE) were assessed: the proportion of
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deaths at the model horizon. Additional simulations
assessed the influence of discounting on the ICERs
results.
The cost of non-persistence was defined as the differ-
ence between costs balance sheet of ideal and real-world
persistence alternatives. Global cost of non-persistence
has been estimated by extrapolation of this result to the
overall population of diagnosed osteoporotic women
estimated at 1.13 million women in France [18]. Cost of
management of fracture, drug cost and sum of both,
were also studied in function of persistence rate.
Table 1 Model inputs
Clinical inputs for transition
probabilities
Values Sources
Baseline features
Age distribution (mean in years) 70.5 Blotman et al. 2007 [7]
Prior fracture (%) 59.7
Fracture probabilities
Absolute risk by age (% per year) Vertebrae Hip Wrist
50-54 years 3.10 0.00 2.99
55-59 years 3.59 0.06 3.20
60-64 years 4.15 0.20 3.18 Cotté et al. 2009 [24]
65-69 years 4.81 0.34 2.06
70-74 years 5.56 0.65 1.97
75-79 years 6.44 1.04 1.17
80-84 years 7.45 1.62 0.92
> 84 years 8.62 3.52 0.92
Relative risk Vertebrae Hip Wrist
associated with any prior fracture at
baseline
2.0 2.0 1.9
post-vertebral fracture health state 4.4 2.3 1.4 Klotzbuecher et al. 2000 [25]
post-hip fracture health state 2.5 2.3 NA
post-wrist fracture health state 1.7 1.9 3.3
Relative risk reduction with BP Vertebrae Hip Wrist
for any women at baseline 0.526 0.672 0.833
from post-vertebral fracture health
state
0.575 0.620 NA Kanis et al. 2002 [9]
from post-hip fracture health state NA 0.620 NA
from post-wrist fracture health state 0.575 0.620 0.566
Loss of bisphosphonate protection
Treatment duration (T; in months) Persistence rates (P;i n
%)
Start 100 Fardellone et al. 2005 [28]
6 65 *Source data were fitted to an exponential function to generate persistence curve
over 24 months:
12 51 P = 1 - 0.196 × ln(T)
24 41
36 30*
48 24*
60 to simulation ending time 20*
Treatment duration (T; in months) Protection duration**
(y; in months)
Start 0 Cotté et al. 2009 [39]
12 24 **Residual effect of BP was modeled as follow:
24 43 y = 13.5 × e
0.048 × T
36 76
48 All simulation period
60 to simulation ending time All simulation period
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Simulation outcomes
After 30,000 patients’ simulations, the total number of
clinical fractures with no treatment alternative achieved
20,701 (Table 3). Real-world treatment persistence and
ideal persistence alternatives decreased this total to
16,711 and 12,378 fractures respectively. Considering
that several fractures could occurred to a same woman,
the number of fractured women was lower than number
of fractures in the three alternatives with 14,258 (49.1%),
12,331 (60.0%) and 9,752 (67.1%) respectively. In the no-
treatment alternative, where the mean start age was 71.1
± 9.7 years, 10,080 (33.6%) were died at the end of the
10-year horizon of the model. Among them, 1,816
(18.0%) died following a clinical fracture (1,052 and 764
at hip and vertebral sites, respectively). Compare to this,
the excess of mortality were reduce by 350 and 801
deaths in the real-world and ideal persistence alterna-
tives, respectively.
Distribution of fracture costs
Within fractured women population, mean costs of 10-
year management of fracture were significantly different
between the three alternatives with €7,239 (± €4,783),
€6,711 (± €4,410) and €6,134 (± €3,945) in the no-treat-
ment, the real-world and ideal persistence alternatives,
respectively (p < 0.0001). The distribution graph showed
left-shifted medians and a spread of costs on the right
side (Figure 2). Compared to no-treatment and real-
world persistence alternatives, all proportions of cost
ranges over €3,000 decreased in the ideal persistence
alternative.
Cost-effectiveness analysis
Cost-effectiveness ratio for real-world treatment persis-
tence compared with no-treatment alternative was
found dominant and as well, alternative of ideal persis-
tence dominated the former (Table 4). One-way sensi-
tivity analysis of discount rate did not affect direction of
those results. However, when bisphosphonates current
branded prices were considered, the cost per fractured
women saved and premature death avoided were respec-
tively €309 and €2,251 for ideal persistence alternative
compared to real-world one.
Cost of non persistence
Ten-year changes in costs of management of fracture
(i.e. nondrug costs) and drug costs in function of persis-
tence are illustrated in Figure 3. Total cost changes,
obtained as sum of drug and nondrug costs, represented
savings from the beginning of a pseudo-linear curve to
the level of ideal persistence (i.e. 100%). Each ten
Table 2 Direct costs of osteoporotic fractures management in France (euros 2010)
Fracture site Hip Wrist Vertebra
Principal diagnosis
Codes S720-S7200 S525-S526 M485(0-9); S22(0-1); S2200; S2210; S320(0); S327(0); S328(0)
Number 53,376 10,394 26,490
Cost of disease-related groups*
Median cost €7,170 €2,615 €2,085
Min-Max costs €1,992 - €15,720 €614 - €3,363 €640 - €15,720
Direct cost of fracture hospitalizations
All fractures €372,849,923 €18,775,427 €93,325,278
Weighted average cost per unit €7,308 €1,844 €3,523
Direct cost of management of fracture**
€11,419 €3,305 €5,872
*DRGs associated with less than 1% of all cases were not taking into account (PMSI 2008).
**Assumption of 40.0%, 36.0% and 44.2% of rehabilitation cost proportion for vertebral, hip and wrist fractures respectively [35]
Table 3 10-year Monte-Carlo simulation outcomes
Monte-Carlo simulations (N = 30,000) No-treatment Real-world persistence Ideal persistence
Clinical fractures Vertebrae 8,193 6,308 3,912
Hip 5,534 4,462 3,313
Wrist 6,674 5,941 5,153
Total 20,401 16,711 12,378
Fractured women
(proportion)
20,131
(67,1%)
17,996
(60.0%)
14,715
(49.1%)
Deaths
(proportion)
1,816
(6.1%)
1,466
(4.9%)
1,015
(3.4%)
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per patient. Hence, the cost of non-persistence as the
difference between total costs of ideal persistence alter-
native and real-world persistence alternative achieved
€270 per patient over the 10-years period. When extra-
polated, this result allowed an estimation of the global
cost of non-persistence in France to €30.5 million per
year.
Discussion
In a context of generic prices, the hypothetical alterna-
tive of ideal persistence with oral bisphosphonates was
shown economically dominant on the real-world persis-
tence. Moreover, the savings came to €58 per patient
for each ten percentage points of persistence gain. The
extrapolated global cost of non-persistence in France
was also estimated to around €30.5 million per year.
Those results demonstrate the extent of the economic
impact of non-persistence with oral bisphosphonates
and as a corollary, the potential lever of improving this
parameter. Although achieving an ideal persistence for
the whole osteoporotic women seems illusive, few stra-
tegies have already demonstrated relevant efficacy in
enhancing persistence. The first of all was the develop-
ment of intermittent administrations allowed by phar-
macokinetics specificity of bisphosphonates [37].
Alendronate and risedronate have been formerly avail-
able with oral daily regimen and then both developed
with oral weekly regimen. Although persistence with
bisphosphonate treatments has been improved with
those weekly formulations, it was still shown to be sub-
optimal in many western countries [12]. The search for
adherence optimization leads other bisphosphonates
providers to develop further the concept of intermittent
dosing regimen. In 2006, ibandronate was the first
within the bisphosphonate class being proposed with a
monthly regimen to post-menopausal women, recently
followed by risedronate [38]. Topical data confirmed
this strategy with a proportion of persistent patients
achieving 17 percentage points higher with monthly
regimen compared to weekly users after 1-year [39].
Seeing the quick and almost full switch of bisphospho-
nates with daily to weekly dosing regimen [7], it is plau-
sible that monthly dosing regimen would become one
day the standard of oral bisphosphonates dosing fre-
quency. However, due to a lack of proven efficacy on
hip site, French authorities recently decided that iban-
dronate would not be reimbursed anymore. Intravenous
Figure 2 Distribution of 10-year fracture cost management.
Table 4 Cost-effectiveness of bisphosphonates for real-world and ideal persistence alternatives
Alternatives No-treatment Real-world persistence Ideal persistence
Costs (Discounted) Average per patients €3,402 €3,110 €2,833
Incremental – -€293* -€277**
Costs (Undiscounted) Average per patients 4,428 €€ 3,979 €3,529
Incremental – -€449* -€450**
Fractured women Proportion 0.671 0.600 0.491
Incremental – -0.071
† -0.109
††
ICER Discounted – (Dominated)
€4,110
(Dominated)
€2,535
Undiscounted – (Dominated)
€6,310
(Dominated)
€4,114
Premature deaths Proportion 0.061 0.049 0.034
Incremental – -0,012
† -0,015
††
ICER Discounted – (Dominated)
€25,073
(Dominated)
€18,442
Undiscounted – (Dominated)
€38,489
(Dominated)
€29,932
* μcReal-world persistence–μcNo treatment;* *μcIdeal persistence–μcReal-world persistence
† μEReal-world persistence–μENo treatment;
†† μEIdeal persistence–μEReal-world persistence
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terly dosing regimen with, in essence, a sustained persis-
tence. Those intravenous bisphosphonates may be
particularly useful to treat patients with a high risk of
non-persistence who could be simply identified by vali-
dated tools, such as the recent ADEOS-12 items ques-
tionnaire [40]. Institutionalized patients may also easily
b e n e f i tf r o mt h o s es p e c i f i ca dministration routes. How-
ever, experience has shown higher patient’s preference
and acceptability for oral administration than for hospi-
tal infusion, in the case of chemotherapy notably [41].
In the past twenty years, the global cost of non-adher-
ence with medications was successively estimated in US
at 20 million lost work days and $1.5 billion in lost earn-
ings annually in 1990 [42], at $100 billion annually in
1997 [43] and finally more than $300 billion annually in
2004 [44]. Outdated but frequently cited in literature
introductions, those macro-economic data suffered from
numbers of methodological biases and have to be used
with caution according to the author of the latter. In gen-
eral, when taking the drug costs into account, it is not
clear whether improving adherence with chronic medica-
tions reduces or increases costs and treatment-specific or
target-population-specific studies are needed. Very few
surveys identified increased healthcare costs due to medi-
cation non-adherence against offsets from reduced drug
intake. In Parkinson’s disease and epilepsy, recent data-
base analyses showed a large net positive effect of non-
adherence on total annual health care costs remained
despite savings in pharmacy costs [45,46].
Four previous studies used mathematical simulation
models to calculate the lost benefits associated with
real-world non-adherence in very different populations:
renal transplanted subjects [47], HIV [48], hypertensive
[49] and schizophrenic patients [50]. Unlike in our pre-
sent results, ideal adherence with renal transplant, HIV
and hypertension medications was not found as a domi-
nant strategy, but cost-effective with €35,000 per Qual-
ity-Adjusted-Life-Year (QALY), $29,400 per QALY and
$22,100 per life-year saved, respectively. In those cases,
results were equivalent of an estimation of the cost-
effectiveness of interventions to improve adherence to
levels observed in clinical trials. The latter study predicts
that increases in compliance with anti-psychotics may
lead to considerable cost savings and health improve-
ments. Hence, each percentage point of compliance gain
was predicted cost saving over 5 years of around €650
and a QALY gain of 0.004. According to our study,
spending up to €270 per osteoporotic patients in an
effective adherence-enhancing intervention would result
in economic neutrality. Over this amount a cost-effec-
tiveness trade-off would be needed. In comparison,
adherence-enhancing interventions to asthmatic and
lipid patients were evaluated as $32 [51] and $182 [52]
offsets, respectively.
Model type, structure, validation have been already
fully discussed in a previous publication as well as its
stability [18]. Estimation of fracture costs were based
from the analysis of an exhaustive National database
and, regarding hip and wrist fractures, were consistent
with previous ones [35]. However, it was not possible to
identified vertebral fractures caused by trauma or malig-
nant tumours from those effectively due to osteoporosis
and, it was assumed that management and also hospita-
lization costs were similar, whatever the original causes
of fractures. Several factors may contribute to a probable
underestimation of the actual costs in this model. The
majority of the vertebral fractures do not require hospi-
talization and were assumed as asymptomatic with no
associated cost. However, many of those fractures prob-
ably lead to other ambulatory resource utilizations (e.g.
back pain treatment). As well, due to the lack of data,
our estimations of fractures costs did not take into
account the patient transport or indirect costs.
Our clinical assumptions and input data were also
clearly stated and justified as required by guidelines for
pharmacoeconomic research. Cost-effectiveness results
were expressed with non conventional ICERs compared
to those mostly used in the literature, especially QALYs.
The latter are actually not recommended by French eco-
nomic evaluation guidelines for public decision making
[53]. Furthermore, outcomes chosen in this model (i.e.
proportion of fractured women and premature deaths)
could be considered as more clinically meaningful than
aggregate ones.
Conclusion
Based on the results of the model, improving persistence
with oral bisphosphonates was shown economically domi-
nant on the real-world persistence. When extrapolated to
Figure 3 Change in drug and nondrug costs in function of
persistence.
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Page 8 of 10the whole of France, savings could rise to over €30 million
per year, with a substantial transfer from hospital to phar-
macy budgets. Pharmacoeconomic environment in the
field of osteoporosis offers new opportunity to optimize
patients’ management on the condition that cost-effective
adherence-enhancing interventions be identified and car-
ried out.
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